Új vizsgálatok, publikációk, preprintek és pályázatok ezen a célponton, hónapról hónapra.
Vizsgálat
Docetaxel Plus Plinabulin vs Docetaxel Plus Placebo in Advanced/Metastatic Non-Squamous NSCLC After PD-1/PD-L1 Therapy and Platinum Chemotherapy (DUBLIN-4)
2026. dec. 1.· PHASE3 · NOT_YET_RECRUITING· CTGOV
Publikáció
Coexistence of ARNT::ALK and TPM3::ALK doublegene fusion in an ALK-rearranged renal cell carcinoma with osseous metaplasia.
2026. nov. 4.· American journal of clinical pathology· PUBMED
Publikáció
EML4-ALK Mediates Resistance to KRASG12C Inhibition and Induces an Oncogenic Dependency by Rewiring Signaling through the Wild-Type RAS Pathway.
2026. nov. 2.· Cancer discovery· PUBMED
Publikáció
Distinct prognostic role of ALK fusion in early and advanced-stage lung adenocarcinoma stratified by clinicopathologic and radiologic features.
2026. nov. 2.· Chinese medical journal· PUBMED
Vizsgálat
Molecularly Stratified Trial for Newly Diagnosed Infant-Type Hemispheric Glioma
2026. nov. 1.· PHASE2 · NOT_YET_RECRUITING· CTGOV
Vizsgálat
Study of SIM0518 in Participants With ALK-Positive or ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
2026. nov. 1.· PHASE1 · NOT_YET_RECRUITING· CTGOV
Publikáció
Diffuse Eruptive Spitz Nevus With Somatic TPM3::ALK Fusion Confirmed Across Anatomically Distinct Lesions.
2026. nov. 1.· Pigment cell & melanoma research· PUBMED
Publikáció
Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer. Reply.
2026. okt. 29.· The New England journal of medicine· PUBMED
Publikáció
Ensartinib in ALK-Positive Non-Small-Cell Lung Cancer.
2026. okt. 29.· The New England journal of medicine· PUBMED
Publikáció
Lorlatinib-Containing Therapy for MYCN-Amplified, ALK-Mutated Neuroblastoma With Bulky Leptomeningeal Relapse: A Case Report.
2026. okt. 29.· Pediatric blood & cancer· PUBMED
Publikáció
Effect of Intratumoral PD-L1 Expression on Treatment Efficacy of ALK Tyrosine Kinase Inhibitors for Advanced or Recurrent ALK-Positive Non-small Cell Lung Cancer.
2026. okt. 26.· Medical oncology (Northwood, London, England)· PUBMED
Publikáció
ASO Visual Abstract: Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma-A Multicenter CReGYT-03 ALK Study.
2026. okt. 23.· Annals of surgical oncology· PUBMED
Publikáció
Comment on "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis".
2026. okt. 23.· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publikáció
[Expert consensus on iruplinalkib for the treatment of ALK fusion gene positive non-small cell lung cancer (2026 edition)].
2026. okt. 23.· Zhonghua zhong liu za zhi [Chinese journal of oncology]· PUBMED
Publikáció
Comment on: "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis": Toward risk-adapted adjuvant therapy beyond ALINA.
2026. okt. 21.· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publikáció
ASO Author Reflections: Rethinking Adjuvant Chemotherapy in Resected ALK-Positive Lung Cancer.
2026. okt. 19.· Annals of surgical oncology· PUBMED
Publikáció
Comment on "Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis": ALK ascertainment and the interpretation of a null result.
2026. okt. 15.· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publikáció
Detection of Actionable Genomic Alterations beyond EGFR, ALK and ROS1 in Non-Small Cell Lung Carcinoma: A Real-World Evaluation of a Pathology-Led Staggered Reflex Predictive Biomarker Testing Strategy in a Resource-Limited Setting.
2026. okt. 14.· Clinical lung cancer· PUBMED
Publikáció
A plain language summary of the 7-year results from the CROWN study: lorlatinib compared with crizotinib in people with ALK-positive non-small cell lung cancer.
2026. okt. 14.· Future oncology (London, England)· PUBMED
Publikáció
Clinical and radiographic improvement in suspected pulmonary lymphangitic carcinomatosis-associated hypoxemic respiratory failure following iruplinalkib-based treatment in ALK-positive lung adenocarcinoma after sequential treatment with ensartinib and lorlatinib: a two-patient case report.
2026. okt. 13.· Frontiers in medicine· PUBMED
Publikáció
Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.
2026. okt. 12.· Current oncology (Toronto, Ont.)· PUBMED
Publikáció
EML4-ALK fusion rewires transcriptomic, miRNA, and CAF-associated programs in non-small cell lung cancer.
2026. okt. 9.· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publikáció
Efficacy and safety of adjuvant ensartinib in stage I ALK-positive NSCLC patients: a retrospective, multicenter study.
2026. okt. 9.· Lung cancer (Amsterdam, Netherlands)· PUBMED
Publikáció
Efficacy and Safety of Alectinib in Pediatric and Adult Patients with ALK-Altered Advanced Solid Tumors: a phase II TACKLE Trial (NCCH1712/MK003).
2026. okt. 8.· Clinical cancer research : an official journal of the American Association for Cancer Research· PUBMED
Publikáció
Subdural Hematoma During Lorlatinib-Induced Regression of Leptomeningeal Carcinomatosis with Suspected Dural Involvement in ALK-Positive Lung Adenocarcinoma.
2026. okt. 8.· Internal medicine (Tokyo, Japan)· PUBMED
Publikáció
Impact of ALK rearrangement on survival in resected lung adenocarcinoma: A real-world analysis.
2026. okt. 7.· Journal of the Formosan Medical Association = Taiwan yi zhi· PUBMED
Publikáció
Real-world evolution of first-line ALK-positive NSCLC management in Spain.
2026. okt. 6.· Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico· PUBMED
Publikáció
Limited Impact of Adjuvant Chemotherapy in ALK-Positive Stage II-III Lung Adenocarcinoma: A Multicenter CReGYT-03 ALK Study.
2026. okt. 5.· Annals of surgical oncology· PUBMED
Publikáció
Envonalkib Versus Crizotinib in Treatment-Naive ALK-Positive Non-Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study.
2026. okt. 4.· MedComm· PUBMED
Publikáció
A Narrative Review of the Cases of Co-altered EGFR and ALK in Non-small Cell Lung Cancers: An Attempt to Break the Therapeutic Dilemma.
2026. okt. 4.· Cureus· PUBMED